UMIN-CTR Clinical Trial

Unique ID issued by UMIN C000000194
Receipt number R000000247
Scientific Title Phase III trial of neoadjuvant chemotherapy followed by surgery versus surgery alone for bulky stage I/II cervical cancer: Japan Clinical Oncology Group trial (JCOG0102)
Date of disclosure of the study information 2005/09/12
Last modified on 2014/02/21 14:22:30

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Phase III trial of neoadjuvant chemotherapy followed by surgery versus surgery alone for bulky stage I/II cervical cancer: Japan Clinical Oncology Group trial (JCOG0102)

Acronym

Phase III trial of neoadjuvant chemotherapy followed by surgery versus surgery alone for bulky stage I/II cervical cancer: Japan Clinical Oncology Group trial (JCOG0102)

Scientific Title

Phase III trial of neoadjuvant chemotherapy followed by surgery versus surgery alone for bulky stage I/II cervical cancer: Japan Clinical Oncology Group trial (JCOG0102)

Scientific Title:Acronym

Phase III trial of neoadjuvant chemotherapy followed by surgery versus surgery alone for bulky stage I/II cervical cancer: Japan Clinical Oncology Group trial (JCOG0102)

Region

Japan


Condition

Condition

Patients with cervical cancer

Classification by specialty

Obstetrics and Gynecology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To investigate the clinical benefits of neadjuvant chemotherapy for bulky stage I/II cervical cancer

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2


Developmental phase

Phase III


Assessment

Primary outcomes

overall survival

Key secondary outcomes

progression-free survival, complication of surgery, completeness of radical hysterectomy, ommission of postsurgical irradiation, completeness of postsurgical irradiation, response rate, adverse events


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

NO

Dynamic allocation

YES

Institution consideration

Institution is considered as adjustment factor in dynamic allocation.

Blocking

NO

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine Maneuver

Interventions/Control_1

A: neoadjuvant chemotherapy + radical hysterectomy

Interventions/Control_2

B: Radical hysterectomy

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

70 years-old >=

Gender

Female

Key inclusion criteria

1) Untreated cervical cancer
2) Pathologically diagnosed squamous carcinoma
3) FIGO stage Ib2, IIa (>4cm), and IIb
4) Measurable lesions
5) Possible to radical hysterectomy
6) Age: 20 to 70 years
7) PS: 0 and 1
8) WBC > 3,000/mm3, Hb > 9.0g/dl, Platelet > 100,000 /mm3, SGOT/SGPT < 60 IU/L, T-Bil < 1.5 mg/dL, Cr < 1.2 mg/dL, PaO2 > 80 torr, normal ECG
9) Written informed consent

Key exclusion criteria

1) Patients who have any evidence of the other cancer present within the last 5 years with the exception of carcinoma in situ or intramucosal cancer those are curable with local therapy
2) Women during pregnancy or breast-feeding
3) Patients with psychiatric illness
4) Patients who have active infectoin
5) Patients who have uncontrolled diabetes or uncontrolled hypertension
6) Patients who have positive HBs
7) Patients who have had heart failure, unstable angina, or myocardial infarction within the past 6 months
8) Patients with interstitial pneumonitis or pulmonary fibrosis
9) Patients who are unable to undergo radical hysterectomy for complication of excessive obesity, liver cirrhosis, or bleeding tendency

Target sample size

200


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Toshiharu Kamura, MD, PhD

Organization

Kurume University

Division name

Obstetrics and Gynecology

Zip code


Address

67 Asahi-machi, Kurume-city, Fukuoka Prefecture 830-0011, JAPAN

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name Noriyuki Katsumata ,MD

Organization

JCOG0102 Coordinating Office

Division name

Medical Oncology Division, National Cancer Center Hospital

Zip code


Address

5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, JAPAN

TEL


Homepage URL

http://www.jcog.jp/

Email

JCOG_sir@ml.jcog.jp


Sponsor or person

Institute

Japan Clinical Oncology Group(JCOG)

Institute

Department

Personal name



Funding Source

Organization

Ministry of Health, Labour and Welfare

Organization

Division

Category of Funding Organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

YES

Study ID_1

NCT00190528

Org. issuing International ID_1

ClinicalTrials.gov by NLM

Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

北海道大学医学部(北海道)
札幌医科大学(北海道)
東北大学医学部(宮城県)
筑波大学臨床医学系(茨城県)
群馬県立がんセンター(群馬県)
防衛医科大学校(埼玉県)
埼玉県立がんセンター(埼玉県)
埼玉医科大学総合医療センター(埼玉県)
国立がんセンター中央病院(東京都)
東京慈恵会医科大学附属病院(東京都)
癌研究会附属病院(東京都)
東京大学医学部(東京都)
順天堂大学医学部(東京都)
新潟県立がんセンター新潟病院(新潟県)
長岡赤十字病院(新潟県)
信州大学医学部(長野県)
愛知県がんセンター(愛知県)
国立病院機構名古屋医療センター(愛知県)
近畿大学医学部(大阪府)
大阪府立成人病センター(大阪府)
大阪市立医療センター(大阪府)
兵庫県立成人病センター(兵庫県)
鳥取大学(鳥取県)
国立病院機構呉医療センター・中国がんセンター(広島県)
国立病院機構四国がんセンター(愛媛県)
国立病院機構九州がんセンター(福岡県)
久留米大学医学部(福岡県)
九州大学病院(福岡県)
佐賀大学医学部(佐賀県)
鹿児島市立病院(鹿児島県)


Other administrative information

Date of disclosure of the study information

2005 Year 09 Month 12 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications

http://www.ncbi.nlm.nih.gov/pubmed/23640393

Number of participants that the trial has enrolled


Results

See the datails via "URL releasing results" above.
Also the details can be seen in the JCOG website:
http://www.jcog.jp/en/trials/index.html

Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2001 Year 10 Month 25 Day

Date of IRB


Anticipated trial start date

2002 Year 02 Month 01 Day

Last follow-up date

2009 Year 02 Month 01 Day

Date of closure to data entry

2009 Year 02 Month 01 Day

Date trial data considered complete

2009 Year 02 Month 01 Day

Date analysis concluded

2009 Year 02 Month 01 Day


Other

Other related information



Management information

Registered date

2005 Year 09 Month 12 Day

Last modified on

2014 Year 02 Month 21 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000247


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name